Showing 3141-3150 of 5255 results for "".
- EULAR News: Tremyfa Data Shows Sustained Improvements in PsAhttps://practicaldermatology.com/news/eular-news-tremyfa-data-showing-sustained-improvements-in-psa/2461755/Tremfya (guselkumab) provides sustainable improvements in all minimal disease activity (MDA) domains through week 48 in adults with active psoriatic arthritis (PsA) who previously had an inadequate response to one to two tumor necrosis factor inhibitors (TNFi-IR), according to new data
- Melanoma Metastasis Discovery: Skin Cancer Rewires Energy Systems to Spreadhttps://practicaldermatology.com/news/melanoma-metastasis-discovery-skin-cancer-rewires-energy-systems-to-spread/2461743/Melanoma skin cancer cells may rewire their internal power systems to drive their spread to other parts of the body, a new study suggests. The research, led by investigators at Barts Cancer Institute, Queen Mary Unive
- And the Winners Are...Mary Kay, ESDR Announce New Grant Recipientshttps://practicaldermatology.com/news/and-the-winners-are-mary-kay-esdr-announce-new-grant-recipients/2461724/Mary Kay Inc. and
- More Phase 3 Data: Dermavant’s VTAMA Hits Primary and Secondary Endpoints for Kids and Adults with ADhttps://practicaldermatology.com/news/phase-3-data-dermavants-vtama-hits-primary-and-secondary-endpoints-for-kids-and-adults-with-ad/2461720/Dermavant Sciences’ VTAMA performed well in in adults and kids with atopic dermatitis, according to topline results from ADORING 1, the company’s second atopic dermatitis (AD) Phase 3 trial. VTAMA is a novel, aryl hydrocarbon receptor agonist, in development a
- Nielsen BioSciences, Maruho Co. Ltd. Enter License Agreement for the Treatment of Common Wartshttps://practicaldermatology.com/news/nielsen-biosciences-maruho-co-ltd-enter-license-agreement-for-the-treatment-of-common-warts/2461719/Nielsen BioSciences, Inc.</
- Online Exclusive: New Practice-changing Research Links ARD to Bacteriahttps://practicaldermatology.com/news/online-exclusive-new-practice-changing-research-links-rad-to-bacteria/2461701/As many as 95% of people undergoing radiation treatment for cancer will develop acute radiation dermatitis (ARD). Little, however, has been known about why this condition occurs, and there are no widely adapted or standardized treatments for preventing severe ARD. New research may chang
- Study: DecisionDx-Melanoma May Lead to Earlier Melanoma Detection, Decreased Metastatic Tumor Burdenhttps://practicaldermatology.com/news/study-decisiondx-melanoma-may-lead-to-earlier-melanoma-detection-decreased-metastatic-tumor-burden/2461698/The use of Castle Biosciences, Inc. DecisionDx-Melanoma test results to guide radiological surveillance may lead to improved patient outcomes, according to a new study in Archives of Dermatological Research. The new study, conducted at three National Cancer Institute-desig
- USPSTF Final Recommendation: There’s Not Enough Evidence to Support Skin Cancer Screening in Folks Without Symptomshttps://practicaldermatology.com/news/uspstf-final-recommendation-theres-not-enough-evidence-to-support-skin-cancer-screening-in-folks-without-symptoms/2461665/
- EULAR News: Acelyrin's IL-17A Blocker Performs Well in PsAhttps://practicaldermatology.com/news/eular-news-acelyrins-il-17a-blocker-performs-well-in-psa/2461657/ACELYRIN, INC.’s IL-17A blocker izokibep demonstrated higher levels of response across psoriatic arthritis disease manifestations, according to 46-week data from a global Phase 2 trial of izokibep in psoriatic arthritis (PsA). Izokibep is a small pr
- PHC Corporation, NovaScan Collab Set to Explore NMSC Detection Devicehttps://practicaldermatology.com/news/phc-corporation-novascan-collab-set-to-explore-nmsc-detection-device/2461644/PHC Corporation and